Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pembrolizumab) in Participants With Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
Amgen
154 participants
Sep 12, 2024
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered by intravenous (IV) injection.
Administered by IV injection.
Locations(128)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06430866